Skip to content

The study to evaluate the efficacy and safety of 675-nm Red Laser in treatment of androgenetic alopecia in Asian males

The study to evaluate the efficacy and safety of 675-nm Red Laser in treatment of androgenetic alopecia in Asian males

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
TCTR
Registry ID
TCTR20251208001
Enrollment
20
Registered
2025-12-08
Start date
2025-03-13
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients diagnosed with androgenetic alopecia (AGA), classified as Norwood-Hamilton scale grades 2-4 and have not undergone any treatment within the 6 months prior to study enrollment. androgenetic alopecia

Interventions

Patients underwent 10 treatment sessions of 675-nm laser, scheduled twice weekly for 5 consecutive weeks.
Experimental Device
Laser

Sponsors

Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
20 Years to 60 Years

Inclusion criteria

Inclusion criteria: - Male patients - Age 20-60 years old - Patients diagnosed with androgenetic alopecia (AGA), classified as Norwood-Hamilton scale grades 2-4 and have not undergone any treatment within the 6 months prior to study enrollment.

Exclusion criteria

Exclusion criteria: - Patients with a history of hair disorders other than androgenetic alopecia. - Patients with a history of collagen disorders such as Cushing syndrome or Ehlers-Danlos syndrome. - Patients who have previously undergone laser therapy or radiotherapy on the scalp. - Patients who smoke or have a history of heavy alcohol consumption. - Patients with dermatitis, wounds, or skin infections in the treatment area. - Patients with a history of thyroid disease or liver disease. - Patients with a history of cancer, currently receiving cancer treatment, or with skin cancer in the treatment area. - Patients with a history of immunodeficiency, including HIV infection or AIDS. - Patients with a history of abnormal photosensitivity. - Patients who have received topical and/or oral medications, platelet-rich plasma injections, or alternative treatments deemed by the investigator to potentially affect the study within 6 months before enrollment. - Patients with a history of hormone therapy or contraceptive use, both oral and injectable. - Patients with a history of keloids or skin lesions in the treatment area. - Patients with a history of psychiatric disorders.

Design outcomes

Primary

MeasureTime frame
Hair count 1st treatment, 5th treatment, 1 month, 3 months, 6 months Trichoscan,Hair Density 1st treatment, 5th treatment, 1 month, 3 months, 6 months Trichoscan,Hair Thickness 1st treatment, 5th treatment, 1 month, 3 months, 6 months Trichoscan

Secondary

MeasureTime frame
Pain score 1st-10th treatment Visual Analog Scale,Safety 1st-10th treatment Adverse event

Countries

Thailand

Contacts

Public ContactWoraphong Manuskiatti

Faculty of Medicine Siriraj Hospital

woraphong.man@mahidol.ac.th024197000

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026